Literature DB >> 17470752

A population-based survey of multiple sclerosis in Shanghai, China.

Q Cheng1, L Miao, J Zhang, S-J Ding, Z-G Liu, X Wang, X-J Sun, Z-X Zhao, Y-J Song, X-Y Ding, Z-L Guo, Y Yang, S-D Chen, G-X Jiang, S Fredrikson.   

Abstract

OBJECTIVE: To conduct a large population-based survey on multiple sclerosis (MS) prevalence in Shanghai, China.
METHODS: We established a network of physicians, mainly neurologists, for identifying prevalent patients with MS and systematically checked inpatient registers at each hospital in the study area for patients with a diagnosis of MS, neuromyelitis optica, or other demyelinating disorders. MS diagnosis in patients was validated by senior neurologists according to the McDonald criteria.
RESULTS: In total, 123 patients with a validated MS diagnosis from the study population, 8.86 million inhabitants with permanent residence in Shanghai, were alive on the prevalence day. The crude MS prevalence rate was 1.39 cases per 100,000 inhabitants (95% CI: 1.16 to 1.66 cases) in the study population in Shanghai. There were 79 female and 44 male patients with MS, a female-to-male ratio of 1.8. Nearly all (96%) of the patients with validated MS had been examined by MRI.
CONCLUSION: Multiple sclerosis prevalence in Shanghai is in line with that reported for other Asian populations.

Entities:  

Mesh:

Year:  2007        PMID: 17470752     DOI: 10.1212/01.wnl.0000260695.72980.b7

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

1.  Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China.

Authors:  Bing Chen; Min Zhou; Jian Ouyang; Rongfu Zhou; Jingyan Xu; Qiguo Zhang; Yonggong Yang; Yong Xu; Xiaoyan Shao; Li Meng; Jing Wang; Yun Xu; Xiushi Ni; Xueguang Zhang
Journal:  Neurol Sci       Date:  2011-12-08       Impact factor: 3.307

Review 2.  Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics.

Authors:  DeRen Huang
Journal:  Neurosci Bull       Date:  2015-12       Impact factor: 5.203

3.  Impact of disease-modifying therapies on the survival of patients with multiple sclerosis in Taiwan, 1997-2008.

Authors:  Ching-Piao Tsai; Charles Tzu-Chi Lee
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

Review 4.  Review of the diagnosis and clinical features of multiple sclerosis in China.

Authors:  Xiao-Juan Cheng; Li-Zhen Xu
Journal:  Neurosci Bull       Date:  2009-02       Impact factor: 5.203

5.  The Discrepancy of Neurological Diseases between China and Western Countries in Recent Two Decades.

Authors:  Jun Ni; Fei Han; Jing Yuan; Han Wang; Dong-Chao Shen; Yan Xu; Li-Ying Cui
Journal:  Chin Med J (Engl)       Date:  2018-04-20       Impact factor: 2.628

6.  Activities of daily living and lesion position among multiple sclerosis patients by Bayes network.

Authors:  Zhifang Pan; Hongtao Lu; Qi Cheng
Journal:  Neural Regen Res       Date:  2013-05-15       Impact factor: 5.135

7.  Novel Variants Identified in Multiple Sclerosis Patients From Southern China.

Authors:  Hongxuan Wang; Lakhansing Arun Pardeshi; Xiaoming Rong; Enqin Li; Koon Ho Wong; Ying Peng; Ren-He Xu
Journal:  Front Neurol       Date:  2018-07-25       Impact factor: 4.003

8.  Multiple Sclerosis in the Asia Pacific Region: A Systematic Review of a Neglected Neurological Disease.

Authors:  Wing L Cheong; Devi Mohan; Narelle Warren; Daniel D Reidpath
Journal:  Front Neurol       Date:  2018-06-08       Impact factor: 4.003

9.  Impaired cognition is related to microstructural integrity in relapsing remitting multiple sclerosis.

Authors:  Lin Zhao; Angel Ng; Qianyun Chen; Bonnie Lam; Jill Abrigo; Cheryl Au; Vincent C T Mok; Adrian Wong; Alexander Y Lau
Journal:  Ann Clin Transl Neurol       Date:  2020-06-09       Impact factor: 4.511

10.  Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China.

Authors:  Yan Xu; Ningying Mao; Viktor Chirikov; Fen Du; Yu-Chen Yeh; Li Liu; Ruiqi Liu; Xin Gao
Journal:  Clin Drug Investig       Date:  2019-03       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.